Umbilical cord stem cells given after clot removal in acute ischemic stroke
Tests umbilical cord stem cells after clot removal in adults with stroke.
Plain-language title generated from the registry record
Registry title: ARTEMIS: UC-MSCs After Mechanical Thrombectomy for Acute Ischemic Stroke
Key facts
- Where
- Tehran, IranSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07913282, who can take part
Where in Iran
- Firoozgar hospitalTehran, IranNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Royan Stem Cell Technology Company
- Trial code
- NCT07913282
- Record updated
- 3 November 2026
- Original description
This study will evaluate the safety and feasibility of administering umbilical cord-derived mesenchymal stromal cells (UC-MSCs) following mechanical thrombectomy in adults with acute ischemic stroke. Acute ischemic stroke occurs when a blood clot blocks blood flow to part of the brain, potentially causing brain tissue damage and neurological impairment.Read full original descriptionShow less
ARTEMIS: Safety and Feasibility of Intra-arterial Administration of Allogeneic Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) After Mechanical Thrombectomy in Acute Ischemic Stroke - A Phase I Controlled Trial
This study will evaluate the safety and feasibility of administering umbilical cord-derived mesenchymal stromal cells (UC-MSCs) following mechanical thrombectomy in adults with acute ischemic stroke. Acute ischemic stroke occurs when a blood clot blocks blood flow to part of the brain, potentially causing brain tissue damage and neurological impairment.
The study will include 10 adults aged 18 to 70 years. All participants will receive standard stroke care, including mechanical thrombectomy to remove the blood clot. Participants will be randomly assigned to one of two groups.
One group will receive standard care plus a single dose of 20 million UC-MSCs derived from donated umbilical cord tissue. The cells will be delivered through a microcatheter into the artery supplying the affected part of the brain. The other group will receive standard care without the cell treatment. Both groups will receive physical rehabilitation.
Researchers will follow participants for six months. They will monitor health problems and assess recovery, disability, blood markers, and brain scans. The main goal is to determine whether this treatment can be administered safely and feasibly. It is not yet known whether the treatment will improve recovery after stroke.
Inclusion: Age 18 to 70 years; Acute ischemic stroke diagnosed clinically; Acute ischemic stroke confirmed by CT or MRI; Eligible for mechanical thrombectomy that can be performed within six hours of symptom onset; NIHSS score from 6 to 20; Pre-stroke modified Rankin Scale (mRS) score less than 2; Successful reperfusion (mTICI 2b or 3) on angiography after thrombectomy; Written informed consent from the patient or a legally authorized representative.
Exclusion: Previous stroke; Subarachnoid, intraventricular, or intracerebral hemorrhage, or a structural brain lesion such as a tumor, on CT or MRI; Known coagulation or hematologic disorder (e.g., aplastic anemia) or current anticoagulant use (e.g., warfarin); Known hepatic, renal, or heart failure; Myocardial infarction within the past 6 months; History of seizures within the past 6 months; History of cancer; Known intellectual, cognitive (e.g., dementia) or psychiatric disorder that would impair understanding of, or adherence to, study procedures and follow-up; Allergy to contrast media; Uncontrolled blood glucose; Infarct in the cerebellum or brainstem; Small lacunar infarct (lesion smaller than 15-20 mm); Midline shift, cerebral edema, or an infarct in an inaccessible location on CT or MRI; Candidate for decompressive craniectomy; Pregnancy or breastfeeding.